Medicinal product authorization holders are obliged to notify Switzerland’s regulatory authority, Swissmedic, of the companies involved in manufacturing and to have them approved.
Swissmedic has reviewed the quality of the data at its disposal and established that these contain omissions and, in some cases, are incorrect. Swissmedic attributes this situation primarily to the increased regulatory requirements over the years, particularly in relation to the level of detail of the required information.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze